pharmaphorum1y
AZ, Daiichi Sankyo cue up TROP2 drug filing in breast cancer
which generated $1.2 billion in sales last year and according to GlobalData could reach $9 billion by 2029. According to a recent Daiichi Sankyo business update (PDF), Dato-DXd will contribute to ...
pharmaphorum7d
AZ, Daiichi’s TROP2 drug hits the mark in lung cancer
AstraZeneca and partner Daiichi Sankyo have their first phase 3 data for TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) – in lung cancer – in one of the most ...
Clinical Trials Arena on MSN16d
Daiichi Sankyo and AstraZeneca’s Enhertu shows OS improvements in Phase III trial
Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the DESTINY-Gastric04 Phase III trial, regarding the primary endpoint of overall ...